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CpGs via Distinct DNA Binding Domains
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MBD1 is a vertebrate methyl-CpG binding domain protein (MBD) that can bring about repression of
methylated promoter DNA sequences. Like other MBD proteins, MBD1 localizes to nuclear foci that in mice
are rich in methyl-CpG. In methyl-CpG-deficient mouse cells, however, Mbd1 remains localized to hetero-
chromatic foci whereas other MBD proteins become dispersed in the nucleus. We find that Mbd1a, a major
mouse isoform, contains a CXXC domain (CXXC-3) that binds specifically to nonmethylated CpG, suggesting
an explanation for methylation-independent localization. Transfection studies demonstrate that the CXXC-3
domain indeed targets nonmethylated CpG sites in vivo. Repression of nonmethylated reporter genes depends
on the CXXC-3 domain, whereas repression of methylated reporters requires the MBD. Our findings indicate
that MBD1 can interpret the CpG dinucleotide as a repressive signal in vivo regardless of its methylation
status.
Cytosine methylation is the major DNA modification in eu-
karyotes. In vertebrates it is found almost exclusively in the 5
CpG context, where it adds epigenetic information to the
genomic DNA sequence and can function to maintain stable
gene silencing through mitotic cell divisions. In genetic ap-
proaches, DNA methylation has been shown to be essential for
normal development in both mice and frogs (21, 29, 33). Most
CpGs are methylated in mammals, and (due to the mutagenic
nature of 5-methylcytosine) the dinucleotide is much under-
represented in mammalian genomes (3). Exceptions to this
rule are the CpG islands, short CG-rich regions that are found
at the promoter of 60% of human genes, including housekeep-
ing genes and some genes that show a tissue-specific expression
profile (2). Most CpG island promoters remain nonmethylated
irrespective of expression state, but in cases in which methyl-
ation occurs somatically (e.g., at imprinted genes and on the
inactive X chromosome), the associated gene is silenced. Ab-
errant gene silencing in tumors via CpG island methylation is
also well documented (1).
The effect of DNA methylation is due in part to structural
alteration of DNA, which prevents some transcription factors
from binding to their cognate sequences. In addition, DNA
methylation affects chromatin structure (9) due to recruitment
of corepressors and chromatin-modifying activities by proteins
that bind specifically to methylated DNA (24, 27, 30, 37). Most
of the methyl-DNA binding proteins described so far belong to
the MBD family, defined by the methyl-CpG binding domain
(MBD; pfam01429). Proteins containing regions with homol-
ogy to the MBD have been identified in plants and animals, but
not every domain has the ability to bind methylated DNA (17).
MBD1 is a member of the subfamily of MBD proteins that do
bind methylated CpG, which in mammals also includes
MeCP2, MBD2, and MBD4. MBD1 orthologues have been
identified in a range of vertebrates (Fugu rubripes, Xenopus
laevis, and various mammals) but are apparently absent from
invertebrates, including the chordate Ciona intestinalis (17).
The Mbd1 protein is not essential for mouse development, but
Mbd1 null animals have defects in adult neurogenesis and show
elevated aneuploidy in neurons (41).
In keeping with the silencing effect of DNA methylation, the
three MBD proteins MBD1, MBD2, and MeCP2 are all tran-
scriptional repressors (36). A transcriptional repression do-
main (TRD) that represses transcription when fused to the
Gal4 DNA-binding domain has been identified at the C ter-
minus of mammalian MBD1 (26). Unlike MBD2 and MeCP2,
MBD1 does not appear to interact with histone deacetylase 1
(HDAC1) or HDAC2 (26). Also, repression by the TRD is
variably sensitive to trichostatin A, indicating that histone
deacetylase activity is not consistently involved (12, 26). Re-
cently, yeast two-hybrid screening has revealed several protein-
binding partners for MBD1. The histone methyltransferase
enzyme SUV39h1 and p150, a subunit of CAF-1 (chromatin
assembly factor 1), both interact with the MBD (13, 31). MBP,
a methylpurine-DNA glycosylase (39), and MCAF (MBD1-
containing chromatin-associated factor; also named mAM)
(12) both bind to the TRD of MBD1 and appear to act as
corepressors of transcription. Interestingly, MCAF/mAM is a
cofactor for the histone methyltransferase ESET, which causes
transcriptional repression by trimethylating dimethylated ly-
sine 9 of histone H3 (38).
Uniquely among MBD proteins, MBD1 has three zinc-co-
ordinating CXXC domains (zf-CXXC; pfam02008) (8, 11).
Previous work established that the third CXXC domain of
MBD1 (CXXC-3) is differentially spliced in both humans and
mice and that splice variants that contain CXXC-3 show DNA
methylation-independent repression (11). Moreover, MBD1
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was independently cloned as a protein that binds using the
CXXC-3 domain to a promoter element of the fibroblast
growth factor 2 (FGF2) promoter (34). CXXC domains are
also found in other chromatin-associated proteins, including
DNA methyltransferase 1 (DNMT1), mixed lineage leukemia
(MLL), and CpG binding protein (CGBP). In the cases of
CGBP and MLL, DNA sequence-specific binding has been
shown in vitro for the CXXC domains, both of which require
nonmethylated CpG sites (4, 20, 35). Here we establish that the
CXXC-3 in the methyl-CG binding protein Mbd1 also binds
specifically to nonmethylated CpGs in vitro. We use an in vivo
assay to show that this CXXC domain can target nonmethyl-
ated CpGs in living cells and can direct repression of non-
methylated reporter genes by Mbd1.
MATERIALS AND METHODS
Cell lines and transfection. DNA methylation-deficient Dnmt1n/n (21),
p53/, and control p53/ Dnmt1/ mouse embryonic fibroblast lines were
derived from embryonic day 9.5 embryos (I. Ben-Porath and H. Cedar, unpub-
lished data) and maintained in Dulbecco’s modified Eagle’s medium (Gibco)
supplemented with 15% bovine calf serum, nonessential amino acids, sodium
pyruvate, and antibiotics (Gibco). The presence of a homozygous p53 mutation
allows survival of Dnmt1-deficient cells (18). In all mouse cell experiments
described here, both control Dnmt1/ and DNA methylation-deficient
Dnmt1n/n cells were p53/. HeLa cells were grown in Dulbecco’s modified
Eagle’s medium (Gibco) supplemented with 10% bovine calf serum and antibi-
otics (Gibco). Cells were transfected using JetPEI (QBiogene) according to the
manufacturer’s instructions. For reporter assays, cells were transfected in qua-
druplicate. Three wells were analyzed for luciferase activity with luciferase (fire-
fly or Renilla) reporter assays (Promega), and one well was analyzed for expres-
sion with Western blotting using standard procedures.
Plasmids and recombinant protein. Murine Mbd1a cDNA was cloned into
pCMV-Flag-2 (Sigma) to produce pFlag-mMbd1a. pFlag-mMbd1c was con-
structed by replacing the 3 end of the Mbd1a cDNA with the coding sequence
of the alternative 3 end found by 3 rapid amplification of cDNA ends (RACE).
pFlag-mMbd1b and pFlag-mMbd1d were produced by removing exon 10 from
pFlag-mMbd1a and pFlag-mMbd1c, respectively. pcDNA3 constructs containing
untagged Mbd1a to Mbd1d cDNAs were in vitro transcribed and translated using
a TNT kit (Promega) according to the manufacturer’s instructions. The Mbd1a
sequence corresponding to amino acids 1 to 75, 171 to 297, or 349 to 439 was
cloned into pET30b (Novagen) to produce bacterial expression constructs for
His-tagged MBD, CXXC-1/2, or CXXC-3 peptides, respectively. Point mutations
corresponding to R22A (in Mbd1a-R22A and the MBD-R22A peptide) and
C356A (in the CXXC-C356A peptide) (see Fig. 3) were introduced using
QuikChange protocol (Stratagene). Recombinant peptides were purified from
250 ml of induced BL21(DE3) cultures on Ni-nitrilotriacetic acid agarose (Qia-
gen) using the manufacturer’s instructions. Gal4-DBD-MBD1 expression con-
structs were described previously (26). pGL-1.2FGF2 was kindly provided by F.
Gage (University of California, Los Angeles). pRL-TK (which expresses the
luciferase gene under a thymidine kinase [TK] gene promoter) and pGL2 (which
expresses the firefly luciferase gene under control of the simian virus 40 promoter
and enhancer) were from Promega.
Band shifts. Binding reaction mixtures including 0 to 750 ng of purified
His-CXXC-3, 0 to 1,000 ng of purified His-CXXC-1/2, or 0 to 500 ng of purified
His-MBD in 6 mM Tris-Cl (pH 7.5)–6 mM MgCl2–3% glycerol–1 mM dithio-
threitol–150 mM KCl–0.05 g of poly(dAdT)/l (Sigma) were preincubated for
10 min at room temperature before the addition of 25 fmol of end-labeled
double-stranded oligonucleotides. After a further 25 min of incubation at room
temperature, the reaction mixtures were loaded onto 6% polyacrylamide–0.5
Tris-borate-EDTA gels and run 2 h at 240 V at 4°C. Gels were dried onto 3-mm
Whatman paper, and radioactivity was detected using phosphor screening and a
Storm 840 apparatus. The oligonucleotides used for band shifting were as fol-
lows: m0-f (GTAGGCGGTGCTACACGGTTCCTGAAGTG) and m0-r (CAC
TTCAGGAACCGTGTAGCACCGCCTAC), m2-f (GTAGGMGGTGCTACA
MGGTTCCTGAAGTG) and m2-r (CACTTCAGGAACMGTGTAGCACMG
CCTAC), and TG-f (GTAGGTGGTGCTACATGGTTCCTGAAGTG) and
TG-r (CACTTCAGGAACCATGTAGCACCACCTAC). Oligonucleotides
were annealed in 10 mM Tris-Cl (pH 8)–1 mM EDTA–50 mM NaCl as follows:
for CG, m0-r and m0-f were annealed; for mCG, m2-r and m2-f were annealed;
for TG, TG-f and TG-r were annealed; and for hemimethylated (hemi) CG, m0-r
and m2-f were annealed.
Immunostaining and Western blotting. Cells were fixed in 4% paraformalde-
hyde in phosphate-buffered saline (PBS) for 20 min at room temperature fol-
lowed by permeabilization in 0.2% Triton X-100–PBS. Slides were blocked in 3%
bovine serum albumin–PBS before incubation with primary antibody (anti-Flag
M2 [Stratagene], anti-Gal4 [Santa Cruz], or anti-Mbd1 [M245] [Santa Cruz] [all
at 1:1,000]) for 60 min. Following washing and incubation with secondary anti-
body (anti-mouse 594 or anti-rabbit 594; Molecular Probes) (1:1,000), slides were
washed and mounted in Vector shield with DAPI (4,6diamidino-2-phenylin-
dole) (Vector). Images were obtained using a Zeiss microscope fitted with a
charge-coupled device camera and processed using Adobe PhotoShop. For
Western blotting, proteins were resolved by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis and blotted onto a PROTRAN membrane (Schleicher
and Schuell). Blots were blocked in a 5% milk–Tris-buffered saline-T solution,
incubated with primary antibody followed by horseradish peroxidase-conjugated
secondary antibody (anti-rabbit or anti-mouse; Amersham), and visualized using
enhanced chemiluminescence.
RACE and RT-PCR. 3 RACE was performed using Marathon-Ready cDNA
from mouse brain (Clontech) and the Mbd1-specific primer (5-CCACGCTGC
AGTCTGGCTTCCCTAGC) according to the manufacturer’s description. For
reverse transcription-PCR (RT-PCR), TRI reagent (Sigma) was used to purify
total RNA from mouse embryonic fibroblasts. RNA (1 g) was DNase treated
(RQ-DNase; Promega) and reverse transcribed in a 25-l reaction mixture
containing 200 ng of random hexamer primers and 1 U of Moloney murine
leukemia virus reverse transcriptase (Promega). Aliquots (1 l) of the RT reac-
tion mixture were used for PCR.
Southern blotting. Genomic DNA (5 g) from mouse embryonic fibroblasts
(p53/ Dnmt1/, p53/, and Dnmt1n/n) was digested with TaiI (Helena
Biosciences), resolved on a 1.2% agarose gel, and blotted onto Hybond-N mem-
branes. The blot was hybridized with a major satellite probe produced by PCR
using the primers mouse sat-for (CTGTAGGACGTGGAATATGGC) and
mouse sat-rev (CCGTGATTTTCAGTTTTCTCGC) and washed using standard
procedures. The membrane was exposed to a phosphor screen and analyzed on
a Storm 840 apparatus.
RESULTS
Mbd1 splice variants in mouse cells. Several different hu-
man MBD1 splice variants have been described previously (7,
11), whereas at present only two Mbd1-encoding transcripts
(corresponding to Mbd1a and Mbd1b) (Fig. 1C) have been
identified in the mouse (16). These two mouse variants differ
only in the presence or absence of exon 10, which encodes
CXXC-3. A transcript lacking exon 3 has been described pre-
viously (16), but the presence of this transcript gives rise to a
frameshift; hence, no Mbd1 protein is produced. Anti-Mbd1
antibodies directed to the C terminus of the murine protein
specifically recognize three polypeptides in mouse nuclear ex-
tracts that have different mobilities. All bands were unaffected
by phosphatase treatment (data not shown), indicating that
they do not represent phosphorylated forms. To search for
additional isoforms in the mouse, we performed 3 RACE with
cDNA from murine brain where Mbd1 is highly expressed (41).
This identified a novel Mbd1 transcript with an alternative 3
end (exon 15a) (Fig. 1A) encoding the C-terminal sequence
KNPEAKMQ, which is very similar to the C terminus of hu-
man MBD1v1 (11) (Fig. 1B). We named splice isoforms car-
rying this 3 end Mbd1c and Mbd1d (Fig. 1C). Transient ex-
pression of Mbd1c caused repression of a methylated reporter,
indicating that the function of the TRD is not disrupted by the
presence of the alternative C terminus (Fig. 1D). The presence
of the alternative C terminus in brain and cultured murine
fibroblasts was verified by RT-PCR (data not shown). In com-
bination with the differential use of exon 10, there are four
possible Mbd1 transcripts (Fig. 1C). To assign the bands
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present on an anti-Mbd1 Western blot, we in vitro translated
the untagged splice variants and ran them alongside nuclear
extracts (Fig. 1E). The three Mbd1-specific bands comigrate
with Mbd1a, Mbd1b, and Mbd1d, suggesting that these are the
three Mbd1 species found in mouse cells. Transcripts that
contained exon 15a in combination with exon 10 (Mbd1c) were
not detected by either Western blotting or RT-PCR (data not
shown). Although both Mbd1a/b and Mbd1d type C termini
are found in bovine expressed sequence tags (GenBank
AW479704 and BE750602), there are no reports of the
Mbd1a/b C-terminal isoform among more than 16 human ex-
pressed sequence tags, suggesting that it might be absent or a
minor form in Homo sapiens.
Localization of Mbd1 in cells lacking DNA methylation. A
functional MBD directs MBD proteins to the heterochromatic
regions of mouse cells that are brightly stained with DAPI (16,
25). These foci contain the pericentromeric major satellite
repeat that carries about half of all methylated CpGs in the
FIG. 1. Mbd1 isoforms in mouse. (A) Schematic of the murine Mbd1 locus showing the differentially spliced exons (exons 10, 15, and 15a)
shaded in gray. (B) Alignment of the C termini of the predicted MBD1 proteins from the human MBD1v1 (hMBD1), rat MBD1 (rMBD1), and
murine Mbd1a/b (mMBD1a) and Mbd1c/d (mMBD1c) cDNA. (C) Schematic representation of the predicted Mbd1 proteins in mouse. CXXC
domains 1 and 2 are shown shaded in light grey; the differentially spliced CXXC-3 domain is shaded in dark gray. The MBD (cross-hatched) and
TRD (hatched) are indicated, and the novel alternative C terminus is shaded in black. (D) Mbd1a and Mbd1c isoforms both repress a methylated
reporter gene. HeLa cells were transfected with the methylated pGL2 reporter and expression vectors for Mbd1a or Mbd1c. Means and standard
deviations of the luciferase activity of triplicate transfections from a representative experiment are shown. The value for the activity without an
Mbd1 expression vector is arbitrarily set to 1. (E) A Western blot (WB) of in vitro transcription and translation reactions of the possible splice
variants alongside a sample of nuclear extract (NE) from murine fibroblasts. Bands in the NE lane are somewhat bowed due to the high protein
concentration and are therefore aligned at their leading edges. The asterisk marks a cross-reacting band that is not Mbd1.
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mouse genome. Cells deficient in the DNA methyltransferase
Dnmt1 lack methylation at these CpG-rich foci, and Mbd2,
Mecp2, and Mbd4 fail to localize in these cells. It was noted
previously, however, that Mbd1 still localizes to the DAPI
bright foci even in mouse Dnmt1n/n embryonic stem cells (16).
We revisited this finding with Dnmt1n/n mouse embryonic fi-
broblasts that have less than 5% of the normal level of DNA
methylation (Ben-Porath and Cedar, unpublished). These cells
have (as expected) very low levels of DNA methylation in the
mouse major satellite, as demonstrated by Southern blotting
results (Fig. 2B), but retain heterochromatin. Previously, it was
shown that the speckled localization of Mecp2 and Mbd2 is lost
in DNA methylation-deficient cells (16, 25). Mbd1, on the
other hand, localizes to the heterochromatic foci in both the
Dnmt1 wild-type and mutant cells (Fig. 2A), confirming that
the protein is targeted to heterochromatic foci in spite of their
unmethylated status.
Mbd1 has a CpG binding CXXC domain. Mbd1 localization
to heterochromatin in cells that lack DNA methylation could
be due to protein-protein interactions between Mbd1 and an-
other heterochromatic protein. Alternatively, Mbd1 might
bind the satellite regions in these cells by virtue of another
DNA-binding activity in the protein. Recently, two unrelated
proteins, CGBP and MLL, were shown to bind to nonmethy-
lated DNA through the CXXC domain (4, 20, 35). We aligned
the three CXXC domains of Mbd1 with these CpG binding
domains (Fig. 3A). All three Mbd1 regions have the eight
signature cysteines conserved, but (unlike CXXC-1 and
CXXC-2) the third domain (CXXC-3) showed a striking match
throughout the region. We tested the Mbd1 CXXC-3 region
for DNA binding activity in vitro using band shift assays. A
recombinant peptide spanning this region bound to the non-
methylated CG11 probe (23) but did not bind to methylated
CpG (data not shown). The specificity for nonmethylated se-
quences was confirmed using four synthetic 29-mer duplex
probes that contain two CpGs with various methylation states
(Fig. 3B). Again, the CXXC-3 domain complexed with the
nonmethylated substrate but did not bind to the methylated
probe. Weak binding to the hemimethylated probe was ob-
served. Significantly, the Mbd1-CXXC-3 domain did not bind
to a substrate entirely lacking CpGs (TG), demonstrating that
nonmethylated CpGs are necessary and sufficient for binding.
The CXXC-1 and CXXC-2 domains did not show this CpG-
dependent DNA binding activity (Fig. 3C). As the MBD of
Mbd1 binds preferentially to methylated CpGs (Fig. 3D), it
follows that the Mbd1 protein has two DNA-binding domains.
One domain is specific for methylated CpG, and the other
domain is specific for nonmethylated CpG.
Mbd1 localization in methyl-CpG-deficient cells is depen-
dent on the CXXC-3 domain. We next asked whether the
CXXC-3 domain is required for localization of Mbd1 to CpG
sites in vivo. We took advantage of the CpG richness of mouse
satellite DNA, which is found concentrated in multiple hetero-
chromatic foci in mouse cell nuclei. In normal cells, the foci are
FIG. 2. Localization of endogenous Mbd1 in DNA methylation-deficient cells. (A) Immunocytochemistry of Dnmt1/ (left panels) or
Dnmt1n/n (right panels) cells as determined using anti-Mbd1 antibodies (top panels). DNA was counter stained using DAPI (bottom panels).
(B) Southern blot of DNA from Dnmt1/ and Dnmt1n/n cells. TaiI-digested genomic DNA was blotted and probed with a major satellite (sat)
sequence. TaiI cleaves at the sequence ACGT and is blocked by methylation of CpG.
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FIG. 3. The CXXC-3 domain of Mbd1 recognizes nonmethylated CpG. (A) Alignment of the three CXXC domains (CXXC-1, CXXC-2, and
CXXC-3) from Mbd1 with the CXXC domains from DNMT1, MLL, and CGBP. The consensus sequence of the domain is given above. An asterisk
marks cysteine C356 that is mutated in the CXXC-3-C356A peptide. (B and C) Band shifts with probes containing nonmethylated (CG),
methylated (mCG), or hemimethylated CG or a probe lacking CG entirely (TG). (B) Increasing amounts (50, 250, or 750 ng) of recombinant
wild-type CXXC-3 (CxxC-3) or mutant CXXC-3 (CxxC-3-C356A; 750 ng) peptide were added. (C) Increasing amounts (100, 500, or 1,000 ng) of
a peptide spanning CXXC-1 and CXXC-2 (CxxC-1/2) or CXXC-3 (250 ng) were added. (D) Increasing amounts (50, 200, or 500 ng) of
recombinant wild-type (MBD) or mutant (MBD-R22A; 500 ng) MBD peptide were added.
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FIG. 4. Localization of Mbd1 in DNA methylation-deficient cells requires the CXXC-3 domain. (A) Schematic representation of the Flag-
Mbd1a expression constructs employed. The positions of the MBD (cross-hatched), CXXC-3 (dark gray), and the TRD (hatched) are shown. The
CXXC-1 and CXXC-2 positions are shown shaded in light gray, and the Flag tag position is dotted. An asterisk marks the point mutations in the
MBD (R22A), and “” marks the sites of deletion of CXXC-3 or the TRD. (B) Diagram illustrating the enrichment for methyl CpG or nonmethyl
CpG in the heterochromatic regions of wild-type (Dnmt1/) or methylation-deficient (Dnmt1n/n) cells, respectively. Methyl-CpG is shown with
filled circles and nonmethyl-CpGs with open circles. The heterochromatic regions are represented by lightly shaded boxes. (C) Dnmt1/ (panels
a to d) or Dnmt1n/n (panels e to h) mouse embryonic fibroblasts were transfected with constructs expressing Flag-tagged Mbd1a (either full length
or the indicated mutants). At 48 h after transfection, the cells were fixed and stained using an anti-Flag antibody (left panels). DNA was
counterstained with DAPI (right panels). (D) Schematic of Gal4-DBD-MBD1 fusion constructs analyzed for colocalization with heterochromatic
foci in Dnmt1/ or Dnmt1n/n mouse embryonic fibroblasts. A plus sign indicates colocalization with heterochromatic foci in Dnmt1n/n cells and
diffuse staining in Dnmt1/ cells, whereas a minus sign indicates diffuse staining in cells of either genotype. The fusion constructs encode amino
acids 81 to 556, 261 to 556, and 261 to 346 of the MBD1 isoform PCM1. The Gal4-DBD is shown in black. CXXC-2 is shown shaded in light gray,
CXXC-3 is shown shaded in dark gray, and the TRD is hatched. (Lower panels) Colocalization with heterochromatic foci of the Gal4-DBD-MBD1
(amino acids 261 to 346) (Gal4-DBD-CXXC-3) in Dnmt1n/n cells is shown.
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methyl-CpG dense, but in Dnmt1n/n cells, they contain high
concentrations of nonmethylated CpG (Fig. 4B). By comparing
the localization characteristics of exogenous Mbd1 forms in
each cell type, we were able to ask which domains of the
protein were required for binding to methylated and non-
methylated DNA. Flag-tagged full-length Mbd1a and various
mutants were expressed, and their localization was assayed by
immunostaining with anti-Flag antibodies. Like the endoge-
nous protein, recombinant full-length Mbd1a protein localized
to the CpG-rich heterochromatic foci in both the wild-type and
the methylation-deficient cells (Fig. 4C, panels a and e). In
wild-type cells, heterochromatic localization was lost in Mbd1
mutants that lack the ability to bind methylated DNA either by
introduction of the R22A point mutation, which abolishes
DNA binding of the MBD (28), or by deletion of the MBD
(Fig. 4C, panel b, and data not shown). Deletion of the
CXXC-3 domain had no effect on localization in these cells.
The picture was strikingly reversed in the methylation-deficient
cells, in which a functional MBD is dispensable for focal lo-
calization of Mbd1 (Fig. 4C, panel f, and data not shown).
Deletion of the CXXC-3 domain resulted in a failure of local-
ization to DAPI-bright regions in these cells and led to dif-
fusely distributed Mbd1 (Fig. 4C, panel g). These results dem-
onstrate that the Mbd1 protein can bind in vivo to
nonmethylated DNA and that this feature depends on the
presence of the CXXC-3 domain. The CXXC-1 and CXXC-2
domains were by themselves unable to target MBD1 to either
methylated or nonmethylated DNA in vivo (Fig. 4C, panel g)
or in bandshift assays in vitro (Fig. 3C). We further found that
the CXXC-1 and CXXC-2 domains are not required to assist
CXXC-3 targeting, as the CXXC-3 domain alone efficiently
targeted nonmethylated DNA in vivo (Fig. 4D).
Mbd1 represses transcription from nonmethylated as well
as methylated templates. DNA methylation correlates with
and can cause transcriptional repression, whereas nonmethyl-
ated promoters are usually in a transcriptionally competent or
active state. Does binding of Mbd1 to nonmethylated CpGs
bring about transcriptional repression or activation? To answer
this question, we cotransfected reporter plasmids with the var-
ious Mbd1 expression constructs into HeLa cells. We did not
include an internal standard in the experiments, as this too
would be affected by a CpG-binding transcription factor. To
ensure uniform transfection efficiency, the levels of Flag-Mbd1
expression were monitored by Western blotting and the exper-
iments were performed in triplicate and repeated three to six
times. Variation between experiments was found to be small.
We established that full-length Mbd1a efficiently repressed
both methylated and nonmethylated constructs (Fig. 5A). Re-
pression of the nonmethylated reporter depended on an intact
CXXC-3 domain, whereas a functional MBD was dispensable.
FIG. 5. CXXC-3 is required for transcriptional repression of a non-
methylated reporter construct by Mbd1. (A and B) HeLa cells were
transfected with constructs expressing Flag-Mbd1a or mutant deriva-
tives plus a TK promoter-driven reporter construct. (A) Luciferase
activities of methylated (Meth) or nonmethylated (Non-meth) re-
porter constructs are shown. Means and standard deviations of tripli-
cate transfections from a representative experiment are shown. The
result of an anti-MBD1 Western blot of whole-cell lysates of cells
transfected in parallel (nonmethylated reporter) is shown in the bot-
tom panel. (B) Repression of a nonmethylated reporter by Mbd1a is
enhanced by the TRD. The graph plots severalfold repression of lu-
ciferase activity from a nonmethylated pRL-TK construct by the indi-
cated amounts of a cotransfected construct expressing Mbd1a or
Mbd1a lacking the TRD (Mbd1-TRD) (Fig. 4A). Error bars show
standard deviations of three data sets.
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The somewhat increased luciferase activity in cells transfected
with constructs lacking CXXC-3 is most likely due to seques-
tration of a limiting repressing cofactor by the overexpressed
repressor (“squelching”). Conversely, repression of methylated
constructs required an intact MBD but was indifferent to the
presence or absence of the CXXC-3 domain. Equivalent re-
sults were observed with reporter constructs encoding either
Renilla or firefly luciferase and driven by a variety of promoters
(TK, 3-phosphoglycerate kinase, simian virus 40, FGF2, and
cytomegalovirus [data not shown]).
The TRD has previously been shown to be necessary for
repression when MBD1 is tethered upstream of a promoter
(26). To ask whether repression of nonmethylated reporters
depends on the TRD, we coexpressed Mbd1a lacking the TRD
with a nonmethylated reporter. The results showed signifi-
cantly reduced repression in the absence of the TRD (Fig. 5B).
Residual repression by the truncated protein may be due to the
presence of other repression domains within Mbd1 or to steric
interference upon binding of the CXXC-3 domain to CpGs
within the reporter transcription unit.
DISCUSSION
MBD1 (initially called PCM1) was identified as a protein
that binds specifically to methylated CpG dinucleotides in
DNA. We show here that a major Mbd1 isoform also contains
the CXXC-3 domain that binds specifically to the nonmethyl-
ated CpG dinucleotide. In vitro binding to nonmethylated
CpG has been established previously for CXXC domains from
CGBP and MLL (4, 20). The binding specificity of these pro-
teins in vivo has been unclear, however. CGBP accumulates in
nuclear sites of transcriptional activity, and this localization is
not disrupted by mutation of the DNA-binding CXXC domain
(19). By analyzing intranuclear localization of wild-type and
mutant versions of Mbd1, we were able to establish that the
CXXC-3 domain specifically localizes Mbd1 to nonmethylated
CpGs in vivo. Localization to CpG-rich foci was disrupted
either by methylation of the target CpG-rich foci or by muta-
tion of the CXXC-3 domain. The MBD1 protein therefore
makes use of two distinct DNA binding domains to target
CpGs, the MBD requiring methylated CpG and the CXXC-3
domain requiring nonmethylated CpG. Although only some
MBD1 isoforms carry the CXXC-3 DNA binding domain, this
new finding affects the previous view of MBD1 as a protein
that exclusively interprets the DNA methylation signal.
The biological significance of the dual DNA binding capa-
bility of MBD1 is currently unknown, but several possible
scenarios can be considered. (i) The MBD and CXXC-3 do-
mains may confer indifference to the methylation state of CpG
sites, allowing MBD1 to function at certain CpGs regardless of
their methylation status. (ii) The CXXC-3-containing isoform
might be targeted to nonmethylated CpGs, where it could
repress expression of CpG island promoters at tissue-specific
genes in nonexpressing tissues—e.g., human alpha globin, neu-
rofilament, and erythropoietin genes. (iii) MBD1 might utilize
the CXXC-3 and MBD regions at the same time to bind a
contiguous DNA sequence containing both a CpG and a meth-
yl-CpG motif. Simultaneous usage of both DNA binding do-
mains may increase the affinity of MBD1 for DNA, as both the
MBD and the CXXC domain recognize a very short sequence
and each domain alone has a moderate binding constant (4,
10). This latter scenario would imply a more gene-specific role
of MBD1, in line with recent findings concerning involvement
of MeCP2 at the murine Bdnf and Xenopus Hairy2A gene
promoters (6, 22, 32).
Concerning the possible role of MBD1 as a repressor of
nonmethylated CpG island promoters (see ii above), it is of
interest that MBD1 was previously found to bind a repeat
element in the human FGF2 CpG island promoter via the
CXXC-3 domain (34). In that study, overexpression of MBD1
down-regulated endogenous FGF2 expression in cultured
cells, suggesting that FGF2 might be an MBD1 target gene.
The MBD1 binding element contains three CpG sites, but we
have found that point mutations that change all three CpGs
within this repeat in an FGF2-luciferase reporter did not abol-
ish repression by MBD1 (data not shown). This suggests that
CpGs elsewhere in the gene might attract repression by
MBD1. Further work is needed to identify bona fide target
genes for MBD1.
The close proximity of the MBD1 and CGBP genes in hu-
mans, mice, rats, and pufferfish suggests an evolutionary an-
cestry for the CXXC domains. Each CXXC is encoded by a
single exon, making exon duplication a likely mechanism for
domain dispersal. Unlike MBD1, CGBP is also found in the
invertebrate C. intestinalis and is therefore the likely ancestor
of the CXXC domains in MBD1. Intriguingly, MBD2, the only
obvious MBD protein found in invertebrate animals, is also
closely linked to MBD1 in both humans and mice (15). It is
therefore possible that both DNA binding domains in MBD1
were donated by neighboring ancestral genes.
Our data indicate that MBD1 has additional TRDs outside
the C-terminal TRD. Previous studies have established inter-
actions between the MBD and potential corepressors
SUV39h1 and the p150 subunit of CAF-1 (13, 31). Similar
involvement of an MBD in corepressor recruitment has been
described for MBD2 (5). There is also evidence that the
CXXC-3 domain itself can bring about transcriptional repres-
sion, as a Gal4 fusion of the MBD1 CXXC-3 region alone was
found to repress transcription in a DNA methylation-indepen-
dent manner (26). The CXXC domains of MLL and DNMT1
both also repress transcription (14, 40). Hence, the CXXC-3
domain and the MBD of MBD1 may each have dual functions:
to bind DNA and to act as docking sites for transcriptional
corepressors.
ACKNOWLEDGMENTS
We are grateful to Howard Cedar for the Dnmt1-deficient cell line
and Karen Wilson for excellent technical assistance. We thank Skir-
mantas Kriaucionis, Eilidh MacDougall, and Jennifer Berger for com-
ments on the manuscript.
This work was funded by a grant from The Wellcome Trust to A.P.B.
REFERENCES
1. Baylin, S. B., M. Esteller, M. R. Rountree, K. E. Bachman, K. Schuebel, and
J. G. Herman. 2001. Aberrant patterns of DNA methylation, chromatin
formation and gene expression in cancer. Hum. Mol. Genet. 10:687–692.
2. Bird, A. 2002. DNA methylation patterns and epigenetic memory. Genes
Dev. 16:6–21.
3. Bird, A. P. 1980. DNA methylation and the frequency of CpG in animal
DNA. Nucleic Acids Res. 8:1499–1504.
4. Birke, M., S. Schreiner, M. P. Garcia-Cuellar, K. Mahr, F. Titgemeyer, and
R. K. Slany. 2002. The MT domain of the proto-oncoprotein MLL binds to
CpG-containing DNA and discriminates against methylation. Nucleic Acids
Res. 30:958–965.
3394 JØRGENSEN ET AL. MOL. CELL. BIOL.
5. Boeke, J., O. Ammerpohl, S. Kegel, U. Moehren, and R. Renkawitz. 2000.
The minimal repression domain of MBD2b overlaps with the methyl-CpG-
binding domain and binds directly to Sin3A. J. Biol. Chem. 275:34963–34967.
6. Chen, W. G., Q. Chang, Y. Lin, A. Meissner, A. E. West, E. C. Griffith, R.
Jaenisch, and M. E. Greenberg. 2003. Derepression of BDNF transcription
involves calcium-dependent phosphorylation of MeCP2. Science 302:885–
889.
7. Cross, S. H., V. H. Clark, and A. P. Bird. 1999. Isolation of CpG islands from
large genomic clones. Nucleic Acids Res. 27:2099–2107.
8. Cross, S. H., R. R. Meehan, X. Nan, and A. Bird. 1997. A component of the
transcriptional repressor MeCP1 shares a motif with DNA methyltransferase
and HRX proteins. Nat. Genet. 16:256–259.
9. Fournier, C., Y. Goto, E. Ballestar, K. Delaval, A. M. Hever, M. Esteller, and
R. Feil. 2002. Allele-specific histone lysine methylation marks regulatory
regions at imprinted mouse genes. EMBO J. 21:6560–6570.
10. Fraga, M. F., E. Ballestar, G. Montoya, P. Taysavang, P. A. Wade, and M.
Esteller. 2003. The affinity of different MBD proteins for a specific methyl-
ated locus depends on their intrinsic binding properties. Nucleic Acids Res.
31:1765–1774.
11. Fujita, N., S. Takebayashi, K. Okumura, S. Kudo, T. Chiba, H. Saya, and M.
Nakao. 1999. Methylation-mediated transcriptional silencing in euchromatin
by methyl-CpG binding protein MBD1 isoforms. Mol. Cell. Biol. 19:6415–
6426.
12. Fujita, N., S. Watanabe, T. Ichimura, Y. Ohkuma, T. Chiba, H. Saya, and M.
Nakao. 2003. MCAF mediates MBD1-dependent transcriptional repression.
Mol. Cell. Biol. 23:2834–2843.
13. Fujita, N., S. Watanabe, T. Ichimura, S. Tsuruzoe, Y. Shinkai, M. Tachi-
bana, T. Chiba, and M. Nakao. 2003. Methyl-CpG binding domain 1
(MBD1) interacts with the Suv39h1-HP1 heterochromatic complex for DNA
methylation-based transcriptional repression. J. Biol. Chem. 278:24132–
24138.
14. Fuks, F., W. A. Burgers, A. Brehm, L. Hughes-Davies, and T. Kouzarides.
2000. DNA methyltransferase Dnmt1 associates with histone deacetylase
activity. Nat. Genet. 24:88–91.
15. Hendrich, B., C. Abbott, H. McQueen, D. Chambers, S. Cross, and A. Bird.
1999. Genomic structure and chromosomal mapping of the murine and
human Mbd1, Mbd2, Mbd3, and Mbd4 genes. Mamm Genome. 10:906–912.
16. Hendrich, B., and A. Bird. 1998. Identification and characterization of a
family of mammalian methyl-CpG binding proteins. Mol. Cell. Biol. 18:
6538–6547.
17. Hendrich, B., and S. Tweedie. 2003. The methyl-CpG binding domain and
the evolving role of DNA methylation in animals. Trends Genet. 19:269–277.
18. Jackson-Grusby, L., C. Beard, R. Possemato, M. Tudor, D. Fambrough, G.
Csankovszki, J. Dausman, P. Lee, C. Wilson, E. Lander, and R. Jaenisch.
2001. Loss of genomic methylation causes p53-dependent apoptosis and
epigenetic deregulation. Nat. Genet. 27:31–39.
19. Lee, J. H., and D. G. Skalnik. 2002. CpG-binding protein is a nuclear matrix-
and euchromatin-associated protein localized to nuclear speckles containing
human trithorax. Identification of nuclear matrix targeting signals. J. Biol.
Chem. 277:42259–42267.
20. Lee, J. H., K. S. Voo, and D. G. Skalnik. 2001. Identification and character-
ization of the DNA binding domain of CpG-binding protein. J. Biol. Chem.
276:44669–44676.
21. Li, E., T. H. Bestor, and R. Jaenisch. 1992. Targeted mutation of the DNA
methyltransferase gene results in embryonic lethality. Cell 69:915–926.
22. Martinowich, K., D. Hattori, H. Wu, S. Fouse, F. He, Y. Hu, G. Fan, and Y. E.
Sun. 2003. DNA methylation-related chromatin remodeling in activity-de-
pendent BDNF gene regulation. Science 302:890–893.
23. Meehan, R. R., J. D. Lewis, S. McKay, E. L. Kleiner, and A. P. Bird. 1989.
Identification of a mammalian protein that binds specifically to DNA con-
taining methylated CpGs. Cell 58:499–507.
24. Nan, X., H. H. Ng, C. A. Johnson, C. D. Laherty, B. M. Turner, R. N.
Eisenman, and A. Bird. 1998. Transcriptional repression by the methyl-CpG-
binding protein MeCP2 involves a histone deacetylase complex. Nature
393:386–389.
25. Nan, X., P. Tate, E. Li, and A. Bird. 1996. DNA methylation specifies
chromosomal localization of MeCP2. Mol. Cell. Biol. 16:414–421.
26. Ng, H.-H., P. Jeppesen, and A. Bird. 2000. Active repression of methylated
genes by the chromosomal protein MBD1. Mol. Cell. Biol. 20:1394–1406.
27. Ng, H. H., Y. Zhang, B. Hendrich, C. A. Johnson, B. M. Turner, H. Erdju-
ment-Bromage, P. Tempst, D. Reinberg, and A. Bird. 1999. MBD2 is a
transcriptional repressor belonging to the MeCP1 histone deacetylase com-
plex. Nat. Genet. 23:58–61.
28. Ohki, I., N. Shimotake, N. Fujita, M. Nakao, and M. Shirakawa. 1999.
Solution structure of the methyl-CpG-binding domain of the methylation-
dependent transcriptional repressor MBD1. EMBO J. 18:6653–6661.
29. Okano, M., D. W. Bell, D. A. Haber, and E. Li. 1999. DNA methyltrans-
ferases Dnmt3a and Dnmt3b are essential for de novo methylation and
mammalian development. Cell 99:247–257.
30. Prokhortchouk, A., B. Hendrich, H. Jorgensen, A. Ruzov, M. Wilm, G.
Georgiev, A. Bird, and E. Prokhortchouk. 2001. The p120 catenin partner
Kaiso is a DNA methylation-dependent transcriptional repressor. Genes
Dev. 15:1613–1618.
31. Reese, B. E., K. E. Bachman, S. B. Baylin, and M. R. Rountree. 2003. The
methyl-CpG binding protein MBD1 interacts with the p150 subunit of chro-
matin assembly factor 1. Mol. Cell. Biol. 23:3226–3236.
32. Stancheva, I., A. L. Collins, I. B. Van den Veyver, H. Zoghbi, and R. R.
Meehan. 2003. A mutant form of MeCP2 protein associated with human
Rett syndrome cannot be displaced from methylated DNA by notch in
Xenopus embryos. Mol. Cell 12:425–435.
33. Stancheva, I., and R. R. Meehan. 2000. Transient depletion of xDnmt1 leads
to premature gene activation in Xenopus embryos. Genes Dev. 14:313–327.
34. Ueba, T., B. Kaspar, X. Zhao, and F. H. Gage. 1999. Repression of human
fibroblast growth factor 2 by a novel transcription factor. J. Biol. Chem.
274:10382–10387.
35. Voo, K. S., D. L. Carlone, B. M. Jacobsen, A. Flodin, and D. G. Skalnik. 2000.
Cloning of a mammalian transcriptional activator that binds unmethylated
CpG motifs and shares a CXXC domain with DNA methyltransferase, hu-
man trithorax, and methyl-CpG binding domain protein 1. Mol. Cell. Biol.
20:2108–2121.
36. Wade, P. A. 2001. Methyl CpG binding proteins: coupling chromatin archi-
tecture to gene regulation. Oncogene 20:3166–3173.
37. Wade, P. A., P. L. Jones, D. Vermaak, G. J. Veenstra, A. Imhof, T. Sera, C.
Tse, H. Ge, Y. B. Shi, J. C. Hansen, and A. P. Wolffe. 1998. Histone deacety-
lase directs the dominant silencing of transcription in chromatin: association
with MeCP2 and the Mi-2 chromodomain SWI/SNF ATPase. Cold Spring
Harbor Symp. Quant. Biol. 63:435–445.
38. Wang, H., W. An, R. Cao, L. Xia, H. Erdjument-Bromage, B. Chatton, P.
Tempst, R. G. Roeder, and Y. Zhang. 2003. mAM facilitates conversion by
ESET of dimethyl to trimethyl lysine 9 of histone H3 to cause transcriptional
repression. Mol. Cell 12:475–487.
39. Watanabe, S., T. Ichimura, N. Fujita, S. Tsuruzoe, I. Ohki, M. Shirakawa,
M. Kawasuji, and M. Nakao. 2003. Methylated DNA-binding domain 1 and
methylpurine-DNA glycosylase link transcriptional repression and DNA re-
pair in chromatin. Proc. Natl. Acad. Sci. USA 100:12859–12864.
40. Zeleznik-Le, N. J., A. M. Harden, and J. D. Rowley. 1994. 11q23 transloca-
tions split the “AT-hook” cruciform DNA-binding region and the transcrip-
tional repression domain from the activation domain of the mixed-lineage
leukemia (MLL) gene. Proc. Natl. Acad. Sci. USA 91:10610–10614.
41. Zhao, X., T. Ueba, B. R. Christie, B. Barkho, M. J. McConnell, K. Na-
kashima, E. S. Lein, B. D. Eadie, A. R. Willhoite, A. R. Muotri, R. G.
Summers, J. Chun, K. F. Lee, and F. H. Gage. 2003. Mice lacking methyl-
CpG binding protein 1 have deficits in adult neurogenesis and hippocampal
function. Proc. Natl. Acad. Sci. USA 100:6777–6782.
VOL. 24, 2004 Mbd1 BINDS METHYLATED AND NONMETHYLATED CpGs 3395
